Kathmandu, Sept 3: The Ministry of Health and Population is to start a clinical trial of vaccine against SARS-CoV-2 and cholera. Nepal Health Research Council is set to initiate the clinical trial of mRNA and cholera vaccines against the two diseases.
A meeting of the Council of Ministers, on August 26, decided to give permission for the clinical trial of vaccines against these diseases.
Executive Director at the Council, Dr Pradeep Gyawali said the trial of both vaccines would be started in two weeks.
According to him, the clinical trial of the MRNA vaccine would be conducted at the Dharan-based BP Koirala Institute of Health Sciences (BPKIHS) and that of the cholera vaccine at Dhulikhel Hospital, Kanti Children's Hospital and Nepalgunj medical College Nepalgunj as well as BPKIHS, in collaboration with Deurali Janata Pharmaceuticals.
The third phase of the clinical trial is being started in Nepal after the successful trial of the MRNA first and the second phase by the vaccine producing company.
Dr Gyawali shared that the mRNA vaccine against coronavirus infection produced by the Wallvacs Company of China is to be trialled in Nepal.
It is said the Company will carry out the trial on 28 thousand people and on 3,000 people in Nepal. Accordingly, the third clinical trial would be conducted in BPKIHS, Dharan.
Do not make expressions casting dout on election: EC
14 Apr, 2022CM Bhatta says may New Year 2079 BS inspire positive thinking
14 Apr, 2022Three new cases, 44 recoveries in 24 hours
14 Apr, 2022689 climbers of 84 teams so far acquire permits for climbing various peaks this spring season
14 Apr, 2022How the rising cost of living crisis is impacting Nepal
14 Apr, 2022US military confirms an interstellar meteor collided with Earth
14 Apr, 2022Valneva Covid vaccine approved for use in UK
14 Apr, 2022Chair Prachanda highlights need of unity among Maoist, Communist forces
14 Apr, 2022Ranbir Kapoor and Alia Bhatt: Bollywood toasts star couple on wedding
14 Apr, 2022President Bhandari confers decorations (Photo Feature)
14 Apr, 2022